Sedana Medical submits application for marketing approval in Switzerland
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for marketing approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care in Switzerland.“Through this application, we cover another important European market ahead of our upcoming launch. If all goes well, we expect to be able to launch in the second half of 2021 in the first 15 European countries for which we have already submitted an application. In Switzerland, we expect to be able to launch in 2022," said Christer